Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis
Ramos-Molina, Bruno (Instituto Murciano de Investigación Biosanitaria)
Rossell, Joana (Institut de Recerca Sant Pau)
Pérez-Montes de Oca, Alejandra (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Pardina, E. (Universitat de Barcelona)
Genua, Idoia (Institut de Recerca Sant Pau)
Rojo López, Marina Idalia (Institut de Recerca Sant Pau)
Julián, María Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Julve i Gil, Josep (Institut de Recerca Sant Pau)
Mauricio Puente, Dídac (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), a leading cause of chronic liver disease, has increased worldwide along with the epidemics of obesity and related dysmetabolic conditions characterized by impaired glucose metabolism and insulin signaling, such as type 2 diabetes mellitus (T2D). MASLD can be defined as an excessive accumulation of lipid droplets in hepatocytes that occurs when the hepatic lipid metabolism is totally surpassed. This metabolic lipid inflexibility constitutes a central node in the pathogenesis of MASLD and is frequently linked to the overproduction of lipotoxic species, increased cellular stress, and mitochondrial dysfunction. A compelling body of evidence suggests that the accumulation of lipid species derived from sphingolipid metabolism, such as ceramides, contributes significantly to the structural and functional tissue damage observed in more severe grades of MASLD by triggering inflammatory and fibrogenic mechanisms. In this context, MASLD can further progress to metabolic dysfunction-associated steatohepatitis (MASH), which represents the advanced form of MASLD, and hepatic fibrosis. In this review, we discuss the role of sphingolipid species as drivers of MASH and the mechanisms involved in the disease. In addition, given the absence of approved therapies and the limited options for treating MASH, we discuss the feasibility of therapeutic strategies to protect against MASH and other severe manifestations by modulating sphingolipid metabolism.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Hepatic fibrosis ; Inflammation ; Lipotoxicity ; Mitochondrial dysfunction ; Sphingolipids ; Steatohepatitis ; Steatotic liver
Publicat a:	Frontiers in endocrinology, Vol. 15 (2024) , p. 1400961, ISSN 1664-2392

DOI: 10.3389/fendo.2024.1400961
PMID: 38962680

17 p, 2.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats